Quick Takeaways
- Samuel Bates Martin has 1 issuer position tracked on this page.
- Estimated disclosed ownership value: $341,937.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Samuel Bates Martin
- Location
- Hampton, NJ
- Summary
- The estimated net worth of Samuel Bates Martin is at least $341,937 dollars as of 06 Jan 2026. Samuel Bates Martin is the SVP AND CFO of Celldex Therapeutics, Inc. and owns shares of Celldex Therapeutics, Inc. (CLDX) stock worth about $341.9K.
- Signature
- /s/ Anthony S. Marucci, attorney-in-fact for Samuel Bates Martin
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Samuel Bates Martin and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Celldex Therapeutics, Inc. ($341,937).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Samuel Bates Martin
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc. | Svp And Cfo | $341,937 | 02 Jan 2026 |
Insider Transactions Reported by Samuel Bates Martin:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.